Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 73.93% is in line with its 5-year average of 75.43%, near the low end of its 5-year range (71.73%–79.44%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.31% below its 12-month average of 74.91%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 73.93%.
DEBT TO ASSETS RATIO
73.93%
DEBT TO ASSETS RATIO AVG TTM
74.91%
DEBT TO ASSETS RATIO AVG 3Y
76.25%
DEBT TO ASSETS RATIO AVG 5Y
75.43%
DEBT TO ASSETS RATIO AVG 10Y
75.15%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-1.31%
CURRENT VS 3Y AVG
-3.05%
CURRENT VS 5Y AVG
-1.99%
CURRENT VS 10Y AVG
-1.63%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 660 covered companies
CURRENT VS SECTOR MEDIAN
+73827.54%
vs the sector median at left
Amneal Pharmaceuticals, Inc.
Market Cap
$6.50B
Debt to Assets Ratio
73.93%
TTM Avg
74.91%
3Y Avg
76.25%
5Y Avg
75.43%
Market Cap
$6.52B
Debt to Assets Ratio
0.26%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.59B
Debt to Assets Ratio
0.43%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.97B
Debt to Assets Ratio
0.52%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.91B
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.50B | 73.93% | 74.91% | 76.25% | 75.43% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.52B | 0.26% | N/A | N/A | N/A |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.59B | 0.43% | N/A | N/A | N/A |
| Chemed Corporation (CHE)vs › | $6.66B | 0.21% | N/A | N/A | N/A |
| Immunovant, Inc. (IMVT)vs › | $6.73B | 0.00% | N/A | N/A | N/A |
| GRAIL Inc. (GRAL)vs › | $6.06B | 0.03% | N/A | N/A | N/A |
| Alkermes plc (ALKS)vs › | $7.04B | 0.36% | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.97B | 0.52% | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.91B | 0.05% | N/A | N/A | N/A |
| CG Oncology Inc. (CGON)vs › | $5.80B | 0.01% | N/A | N/A | N/A |
Debt/Assets
73.9%
Debt/Equity
84.54
Current Ratio
2.20
Interest Coverage
1.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 73.93% |
| 2026-03-31 | 76.17% |
| 2025-12-31 | 74.40% |
| 2025-09-30 | 74.61% |
| 2025-06-30 | 75.43% |
| 2025-03-31 | 76.65% |
| 2024-12-31 | 74.06% |
| 2024-09-30 | 76.41% |
| 2024-06-30 | 77.64% |
| 2024-03-31 | 79.44% |
| 2023-12-31 | 79.21% |
| 2023-09-30 | 76.07% |
| 2023-06-30 | 77.24% |
| 2023-03-31 | 78.68% |
| 2022-12-31 | 74.88% |
| 2022-09-30 | 73.76% |
| 2022-06-30 | 71.73% |
| 2022-03-31 | 73.70% |
| 2021-12-31 | 73.29% |
| 2021-09-30 | 73.31% |
| 2021-06-30 | 73.33% |
| 2021-03-31 | 73.74% |
| 2020-12-31 | 74.86% |
| 2020-09-30 | 73.34% |
| 2020-06-30 | 73.32% |
| 2020-03-31 | 74.69% |
| 2019-12-31 | 75.56% |
| 2019-09-30 | 74.87% |
| 2019-06-30 | 65.28% |
| 2019-03-31 | 63.68% |
| 2018-12-31 | 61.83% |
| 2018-09-30 | 62.74% |
| 2018-06-30 | 61.17% |
| 2018-03-31 | 109.04% |
| 2017-12-31 | 110.65% |
| 2017-09-30 | 118.07% |
| 2016-12-31 | 98.25% |
